Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | TACR3 | P29371 | 10/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974172 | 0.97 | CYP2C9 (0.45) | CYP2C9TACR3PPARGSMYD3 | |
| SCHEMBL1978628 | 0.90 | CYP2C9 (0.46) | CYP2C9TACR3PPARGRIPK1PDE2A | |
| SCHEMBL1973915 | 0.90 | PPARG (0.37) | CYP2C9TACR3PPARGRIPK1SMYD3 | |
| SCHEMBL1973525 | 0.89 | FAAH (0.37) | CYP2C9TACR3RIPK1PDE2AKCNK3 | |
| SCHEMBL1975767 | 0.89 | RIPK1 (0.42) | CYP2C9TACR3PPARGRIPK1SMYD3 | |
| SCHEMBL1974989 | 0.86 | CYP2C9 (0.45) | CYP2C9TACR3PPARGRIPK1 | |
| SCHEMBL1974481 | 0.86 | CNR2 (0.40) | CYP2C9TACR3PDE2AKCNK3 | |
| SCHEMBL1973603 | 0.86 | CYP2C9 (0.49) | CYP2C9TACR3PPARGRIPK1PDE2A | |
| SCHEMBL1972416 | 0.86 | CYP2C9 (0.49) | CYP2C9TACR3PPARGRIPK1PDE2A | |
| SCHEMBL1974248 | 0.86 | MEN1 (0.41) | TACR3RIPK1SMYD3KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | claimed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | CYP2C9 2501/4885TACR3 26/4885PPARG 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.